Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368: 1155 63. S4.4.2-26. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.4.2-27. Navar AM, Stone NJ, Martin SS. What to say and how to say it: effective communication for cardiovascular disease prevention. Curr Opin Cardiol. 2016;31:537 44. S4.4.2-28. Laing ST. High-intensity statins: guideline expectations and clinical application. JAMA. 2017;317:2543 4. S4.4.2-29. Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175 6. S4.4.2-30. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardio- vascular risk, is important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975 83. S4.4.2-31. Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardio- vascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340 6. S4.4.2-32. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.4.2-33. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guide- line on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S4.4.2-34. Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA) Circulation. 2016;133:849 58. S4.4.2-35. 